CCR2 and cancer: Additionally, VCAM-1 binding peptide tagged liposomes carrying the CCR2 antagonist can reduce pre-metastatic lung vascular permeability by directly targeting cancer cell-activated endothelium, and thereby prevent tumour cell extravasation [296].